TAE Life Sciences Partners with University of Wisconsin-Madison to Launch First US Accelerator-Based BNCT Cancer Treatment Center
核心洞察
TAE Life Sciences (搜索) and University of Wisconsin-Madison signed a memorandum of understanding to establish the first accelerator-based boron neutron capture therapy (BNCT) center in the United States.
The collaboration will focus on clinical trials for brain and head and neck cancers using the Alphabeam compact accelerator-based BNCT system and novel boron-10 drugs.
BNCT represents a cutting-edge cancer treatment that selectively targets cancer cells while minimizing harm to healthy tissue, with patients requiring only one or two treatment sessions.
TAE Life Sciences (搜索) (TLS), a global leader in advancing next-generation boron neutron capture therapy (BNCT), and the University of Wisconsin–Madison (UW) have signed a memorandum of understanding (MOU) to launch the first accelerator-based BNCT center in the United States. The collaboration positions UW as the intended first US site to install the Alphabeam compact accelerator-based BNCT system and execute the first clinical trials focusing on head and neck and brain cancers.
Revolutionary Cancer Treatment Technology
BNCT represents a cutting-edge cancer treatment that selectively targets cancer cells while minimizing harm to healthy tissue. The therapy is a combination treatment based on the reaction that occurs when a non-toxic compound containing boron-10 is irradiated with a low-energy neutron beam. Research has shown BNCT has the capability of killing cancer cells that are resistant to traditional radiation therapy with limited harm to healthy tissue.
The Alphabeam system offers a breakthrough approach to cancer treatment through combinational therapy utilizing targeted boron-10 drugs and low-energy neutrons to destroy tumors with no damage to healthy tissues. With this system, patients can undergo a short, minimally invasive treatment in just one or two sessions, providing a streamlined alternative to traditional cancer therapies.
Comprehensive Research Collaboration
As part of the proposal, UW and TAE Life Sciences (搜索) will collaborate on research and development of Alphabeam and novel boron-10 drugs through pre-clinical and clinical studies on several cancer indications with high unmet need, including brain and head and neck cancers. TAE Life Sciences is the only company to have a comprehensive BNCT solution that replaces earlier challenges with nuclear reactor-based BNCT and has the potential to establish accelerator-based BNCT as a mainstay cancer treatment in the United States.
"Our collaboration with the esteemed University of Wisconsin–Madison underscores the growing momentum and recognition of BNCT as a transformative cancer therapy," stated Robert Hill, Chief Executive Officer of TAE Life Sciences (搜索). "By working closely with UW and the University of Wisconsin Carbone Cancer Center, a leading cancer center renowned for its commitment to innovation, we aim to revolutionize the landscape for cancer treatment, and make even the most challenging cancers treatable with minimal side effects."
Global Implementation Success
This announcement builds upon the success TAE Life Sciences (搜索) has had deploying its technology globally. To date, the company has installed its neutron beam system in China's Xiamen Humanity Hospital, which is currently running human clinical trials, and its Alphabeam will soon be installed at Italy's National Center of Oncological Hadrontherapy (CNAO). BNCT is currently available in Japan and being evaluated in clinical trials in several other countries.
Clinical Significance and Patient Impact
Dr. Zachary Morris, Chair and Paul Harari Professor of Human Oncology at the University of Wisconsin School of Medicine and Public Health, emphasized the milestone's significance: "Today marks a significant milestone in the field of oncology in the United States. Our collaboration with TAE Life Sciences (搜索) brings together our expertise in clinical radiation medicine, translational research, and theranostics with the accelerator-based BNCT system, enabling us to harness the full potential of this advanced cancer treatment."
To date, approximately 2,000 patients have been treated with BNCT at research sites worldwide. Current advances in both neutron radiation technology and medicinal boron drug targeting are enabling BNCT's potential to improve patient care while also improving treatment economics.
The Alphabeam BNCT system and novel boron-10 drugs are currently for research purposes and not available for sale, with TAE Life Sciences (搜索)' drug and device currently in development and not yet approved for sale.